SEATTLE, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today is celebrating the first shipment and patient dosing from its second manufacturing facility for the production of its 203Pb- and 212Pb-labeled radiopharmaceuticals. Located in Somerset, New Jersey, this facility is now operational to supply investigational produ ...

[212Pb]VMT01 was observed to be safe, and no dose-limiting toxicities were observed at the two doses tested (3.0 and 5.0 mCi) Prolonged progression-free survival and tumor response were observed in heavily pretreated patients who received the low (3.0 mCi) dose of [212Pb]VMT01, consistent with preclinical findings Trial is progressing with testing [212Pb]VMT01 at a lower (1.5mCi) dose to further elucidate the optimal dose for immunostimulatory activities on the tumor microenvironment in melanoma both as mon ...

SEATTLE, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that initial results from its Phase 1/2a study of [212Pb]VMT01 have been selected for a poster presentation at the 21st International Congress of the Society for Melanoma Research ("SMR"), being held on October 10-13, 2024 in New Orleans, Louisiana. Th ...

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

Shares of Perspective Therapeutics Inc (CATX, Financial) surged 3.40% in mid-day trading on Oct 2. The stock reached an intraday high of $13.10, before settling at $13.06, up from its previous close of $12.63. This places CATX 31.44% below its 52-week high of $19.05 and 493.37% above its 52-week low of $2.20. Trading volume was 204,700 shares, 23.9% of the average daily volume of 856,527. Wall Street Analysts Forecast Based on the one-year price targets offered by 8 analysts, the average target price for Pe ...

SEATTLE, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced the Company will present updated preclinical data on PSV359 at the 37th Annual Congress of the European Association of Nuclear Medicine ("EANM"), which is being held in Hamburg, Germany, from October 19-23, 2024. Presentations regarding certain of the ...

SEATTLE, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or "the Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one-on-one meetings with investors at the following upcoming investor conferences. Morgan Stanley 22nd Annual Global Healthcare Conference Date: September 6, 2024 Locat ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to ____________ Commission File Number: 001-33407 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |---------------- ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Perspective Therapeutics (CATX) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question. Perspective Therapeutics is a member of our Medical group, which includes 1019 different companies and currently sits at #3 in the Zacks Sector Rank. The Zacks Sector Rank gau ...

Exhibit 99.1 Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Q1 2024 Results • Continued progress enrolling in its VMT-α-NET and VMT01 clinical trials • Disclosed a new internally discovered molecule that targets fibroblast activation protein-α • Announced the in-licensing of a technology that enables the use of antibodies to direct radiolabeled ligands to tumor sites • Raised $177.2 million in gross proceeds through various financing transactions and raised an additional $49 ...